Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, has received FDA approval for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
The American Cancer Society’s 2026 annual statistics report trumpets a symbolic milestone for oncology—for the first time, the five-year relative survival rate for all cancers combined has reached 70% for people diagnosed between 2015 and 2021 in the U.S.
